Logo

Michael Pellini

Feb 13, 2018

Adaptive Biotechnologies announced that former Foundation Medicine CEO Michael Pellini has joined its board. Pellini is currently chairman of Foundation Medicine's board, and is a managing partner of life science venture capital firm Section 32. He previously was president and chief operating officer of Clarient, which was acquired by GE Healthcare in 2010. He currently also serves on the boards of Tango Therapeutics, Singular Genomics, the Personalized Medicine Coalition, and the Mission Hospital Foundation. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.